News
12-14-2009, 03:52 AM
Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.
More... (http://www.news-medical.net/news/20091214/Genentech-announces-Phase-III-study-of-Avastin-in-women-treated-with-chemotherapy-for-advanced-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20091214/Genentech-announces-Phase-III-study-of-Avastin-in-women-treated-with-chemotherapy-for-advanced-breast-cancer.aspx)